Growth ⏱ Half-life: Approximately 8 days due to albumin conjugation via the DAC moiety. Discontinued

CJC-1295 DAC

CJC-1295 with Drug Affinity Complex

Updated March 15, 2026
Buy Now

Evidence at a Glance

Regulatory statusDiscontinued
GHRH analog with albumin-binding DAC (ConjuChem); reached Phase 2 (NCT00267527, HIV visceral obesity) then development was discontinued; never FDA-approved.
Human evidenceLimited
Animal evidenceModerate

A Phase 1 trial (Teichman 2006) showed sustained GH/IGF-1 elevation and reasonable tolerability, but Phase 2 development was discontinued and it was never approved for any indication.

What the research does not support

  • It was never FDA-approved and its Phase 2 development was discontinued.
  • Raising GH/IGF-1 has not been proven to improve body composition, performance, or longevity.
  • Long-term safety in healthy adults has not been established.
  • It is prohibited in sport by WADA and is not a legitimate anti-aging therapeutic.
Half-Life
Approximately 8 days due to albumin conjugation via the DAC moiety.
Mol. Weight
3647.28 g/mol

What is CJC-1295 DAC?

CJC-1295 DAC is the extended-release version of the GHRH analog CJC-1295, modified with a Drug Affinity Complex that binds to albumin in the bloodstream. This dramatically extends its active duration from minutes to over a week.

Research Applications

Sustained GH axis stimulation, long-term IGF-1 elevation studies, body composition research, and comparative studies against pulsatile GHRH protocols.

Dosage Information (Research Use)

Research protocols: 1-2 mg subcutaneously once or twice weekly. The sustained release reduces injection frequency compared to non-DAC version. Research use only.

Reconstitution & Handling

Standard BAC water reconstitution. Dissolves readily.

Half-Life & Pharmacokinetics

Approximately 8 days due to albumin conjugation via the DAC moiety.

Reported Observations in Literature

Similar to other GHRH analogs: flushing, water retention, tingling. Continuous GH elevation may amplify effects compared to pulsatile protocols.

Key Research References

  • Teichman SL, et al. “Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults.” J Clin Endocrinol Metab. 2006

How CJC-1295 DAC Works

CJC-1295 DAC is the Drug Affinity Complex version of Modified GRF(1-29). The DAC moiety binds covalently to serum albumin after injection, extending the half-life from ~30 minutes to approximately 8 days. This creates sustained, elevated GH levels rather than the pulsatile pattern seen with the no-DAC version. While this produces higher total GH output, the non-physiological continuous elevation has led many researchers to prefer the no-DAC version for more natural pulsatile release patterns.

Research Findings

Published data shows sustained IGF-1 elevation for 7-10 days after a single subcutaneous injection. Less commonly used than the no-DAC variant in modern research protocols due to preference for pulsatile GH release.

Dosage & Administration

Research protocols: 1-2 mg subcutaneously once or twice weekly. The sustained release reduces injection frequency compared to non-DAC version. Research use only.

Safety & Side Effects

Similar to other GHRH analogs: flushing, water retention, tingling. Continuous GH elevation may amplify effects compared to pulsatile protocols.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Modified GRF(1-29) with lysine-linked MPA (maleimidopropionic acid) DAC
Molecular Weight 3647.28 g/mol
Half-Life Approximately 8 days due to albumin conjugation via the DAC moiety.
Available Sizes 2mg, 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C, use within 21 days.

Key Research References

  • Teichman SL, et al. "Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults." J Clin Endocrinol Metab. 2006

Get CJC-1295 DAC from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Buy Now

Related Peptides

View all →
GHRP-2
Growth
Synthetic hexapeptide GH secretagogue considered the gold standard for GH release potency in research with moderate selectivity.
View Profile →
Ipamorelin
Growth
Selective growth hormone secretagogue peptide that stimulates GH release without significantly affecting cortisol or prolactin levels.
View Profile → Buy Now
IGF-1 LR3
Growth
Long-acting IGF-1 analog with extended half-life for sustained anabolic signaling in muscle and tissue research.
View Profile → Buy Now